GAS6

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Toxic epidermal necrolysis, GAS6, AXL, Communication, ORR, Literature, Food, DABT, IO, Risk, TKI, Cancer, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hematology, Progression-free survival, Royal commission, Biomarker, Annual report, Fast Track, Platinum, Endpoint security, European Commission, Tectonic evolution of the Aravalli Mountains, Kidney cancer, PFS, Metastasis, Therapy, Ovarian cancer, Division, Vanderbilt University Medical Center, Assistant professor, FDA, Pharmaceutical industry

Fast Track is a process designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast Track is a process designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and fill an unmet medical need.
  • Drugs with Fast Track Designation may also qualify for accelerated and priority review of new drug applications if relevant criteria are met.
  • The Fast Track Designation was based on new data submitted to the agency from the P1b clear cell renal cell cancer (ccRCC) study (AVB500-RCC-003; NCT04300140).
  • Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer.

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

Retrieved on: 
Monday, November 21, 2022
GAS6, AXL, Cancer, Royal commission, Platinum, European Commission, Metastasis, Therapy, Ovarian cancer, FDA, Real estate, Pharmaceutical industry

If you are interested in requesting a 1x1 meeting at the respective conference, please contact your bank/conference representative.

Key Points: 
  • If you are interested in requesting a 1x1 meeting at the respective conference, please contact your bank/conference representative.
  • Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease.
  • Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum resistant recurrent ovarian cancer.
  • The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, November 16, 2022
GAS6, AXL, Listing Rules, Cancer, Royal commission, Platinum, European Commission, Arav, Metastasis, Therapy, Ovarian cancer, FDA, Pharmaceutical industry

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (Nasdaq) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Key Points: 
  • HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (Nasdaq) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).
  • The Company was previously notified by the Staff at Nasdaq on August 9, 2022 that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules.
  • Since then, the Staff at Nasdaq has determined that for 11 consecutive business days, from October 27, 2022 to November 10, 2022, the closing bid price of the Companys common stock has been at $1.00 per share or greater.
  • Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) and this matter is now closed.

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, November 10, 2022
Platinum, Nivolumab, Serum, Communication, Research, Risk, Population, BLA, US, Company, Biologics license application, CMC, Review, Forward-looking statement, GAS6, Toxic leukoencephalopathy, Pancreatic cancer, Cancer, Genta (company), European Commission, Paclitaxel, SEC, Science, Patient, AXL, COVID-19, Private Securities Litigation Reform Act, Tectonic evolution of the Aravalli Mountains, PDAC, Achievement, Clinical trial, Terminology, DABT, ITT, Metastasis, FDA, GLOBE, PFS, PROC, Annual report, Royal commission, Ovarian cancer, Therapy, Progression-free survival, MEC, ORR, Pharmaceutical industry

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company),a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.
  • Aravive continues to make tremendous progress on all fronts, said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive.
  • The registration-directed Phase 3 program of batiraxcept in combination with paclitaxel in PROC remains on track to complete enrollment aroundyear-end 2022.
  • Revenues for the three months ended September30, 2022, were approximately $4.9 million, compared to approximately $1.6million for the three months ended June 30, 2022.

Aravive Announces Approximately $41.5 Million Private Placement Financing

Retrieved on: 
Tuesday, October 25, 2022
Ovarian cancer, GAS6, Private Securities Litigation Reform Act, Terminology, Securities Act of 1933, Company, U.S. Securities and Exchange Commission, Cancer, Communication, GLOBE, Sale, Annual report, FDA, Tectonic evolution of the Aravalli Mountains, Patient, Quality of life, Platinum, SEC, DABT, Survival, Therapy, LLC, European Commission, PIPE, COVID-19, Paclitaxel, Risk, Exchange, Security (finance), Review, Forward-looking statement, Company Directors Disqualification Act 1986, Partnership, AXL, Doctor of Philosophy, Metastasis, European Network of Transmission System Operators for Electricity, Safety, Pharmaceutical industry, Nasdaq, PROC

The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The private placement is expected to close on October 27th, subject to the satisfaction of customary closing conditions.
  • The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the Minimum Price requirement (as defined in the Nasdaq rules).
  • MTS Securities, LLC, an affiliate of MTS Health Partners L.P., acted as the exclusive placement agent in the financing.
  • This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Aravive Receives Third Development Milestone from 3D Medicines

Retrieved on: 
Monday, October 10, 2022
Quality of life, Communication, European Network of Transmission System Operators for Electricity, Therapy, Risk, SEC, Review, GAS6, Hope, Woman, Platinum, Paclitaxel, Annual report, Patient, Metastasis, Partnership, Private Securities Litigation Reform Act, Company, Ovarian cancer, Marketing, Cancer, AXL, DABT, Safety, Survival, GLOBE, Clinical trial, Forward-looking statement, Tectonic evolution of the Aravalli Mountains, Terminology, COVID-19, PROC, European Commission, FDA, Pharmaceutical industry

HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.

Key Points: 
  • HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.
  • Aravives collaboration and license agreement with 3D Medicines Inc. is for the development and commercialization of batiraxcept in oncology indications in Greater China.
  • Under the terms of the agreement, Aravive is eligible to receive up to an aggregate of $207 million in development and commercial milestone payments and royalties.
  • In addition to achieving this $6 million development milestone, the Company had previously received a $9 million in development milestones related to development of batiraxcept for platinum resistant ovarian cancer in the United States and China, as well as a $12 million upfront payment in 2020, totaling $27 million that has been achieved by Aravive from 3D Medicines.

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

Retrieved on: 
Monday, September 26, 2022
Cancer, Therapy, Tectonic evolution of the Aravalli Mountains, Lotte New York Palace Hotel, FDA, DABT, Ovarian cancer, European Commission, Company, AXL, Metastasis, GAS6, Conference, GLOBE, Royal commission, Platinum, Pharmaceutical industry

Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease.

Key Points: 
  • Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease.
  • Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents.
  • Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer.
  • The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.

Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
GAS6, Metastasis, AXL, Platinum, DABT, Cancer, Royal commission, Tectonic evolution of the Aravalli Mountains, GLOBE, Conference, Company, Therapy, FDA, Lotte New York Palace Hotel, Webcast, Ovarian cancer, European Commission, Event, Pharmaceutical industry

The Companys presentation will be available for viewing on September 12, 2022, at 7:00 am ET.

Key Points: 
  • The Companys presentation will be available for viewing on September 12, 2022, at 7:00 am ET.
  • An archived replay of the webcast will be available for 90 days following the webcast on the Events & Presentations page of www.aravive.com .
  • Aravive will also participate in one-on-one meetings at the conference.
  • Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease.

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, August 11, 2022
Serum, PROC, Risk, ASCO, Metastasis, GLOBE, ORR, SEC, Clinical trial, Research, Annual report, Patient, Paclitaxel, Nivolumab, DABT, KOL, US, PFS, Toxic epidermal necrolysis, ...Continued, Terminology, Addition, Industry, Private Securities Litigation Reform Act, GAS6, BLA, Ovarian cancer, CMC, European Commission, Tectonic evolution of the Aravalli Mountains, Forward-looking statement, COVID-19, ITT, Kidney, Royal commission, Cancer, FDA, Population, Pancreas, Review, Company, Pancreatic cancer, Therapy, Lists of people executed in the United States, AXL, Progression-free survival, Pharmaceutical industry, Online gambling, Platinum, Cancer (disambiguation)

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Key Points: 
  • HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
  • We continued to achieve great progress for Aravive in the second quarter of 2022.
  • Our Phase 1b trial in pancreatic cancer has completed enrollment and updated results are anticipated later this year.
  • Revenues for the three months ended June 30, 2022 were $1.6 million, compared to $1.1 million for the three months ended March 31, 2022.

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

Retrieved on: 
Tuesday, July 5, 2022
Alexion, Patient, Lymphatic system, GLOBE, COVID-19, Cancer, Internal medicine, Company, American Board of Internal Medicine, Physics, DABT, Physician, Drug development, Chicago (franchise), FDA, Arav, BLA, Therapy, SEC, Risk, American Board of Commissioners for Foreign Missions, Forward-looking statement, Probability, Senior, Harvard Medical School, European Commission, Haematopoietic system, Terminology, GAS6, Hospital, Private Securities Litigation Reform Act, Medical Affairs Bureau, Review, Oncology, Annual report, Platinum, 2021 Essex County Council election, Metastasis, Publication, Neoplasm, MIT, University, AXL, Emory University, PROC, Program, Ovarian cancer, Pharmaceutical industry, Science

HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer.

Key Points: 
  • HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the appointment of Dr. Robert B. Geller as Chief Medical Officer.
  • I feel very fortunate and proud that I am able to join Aravive at this critical juncture, as the company nears key value inflection points, stated Dr. Robert B. Geller, Chief Medical Officer of Aravive.
  • Dr. Geller earned Bachelor and Master of Science degrees in Physics at MIT and Medical Doctor degree from Harvard Medical School.
  • Dr. Geller completed a medical residency at the Hospital of the University of Pennsylvania and Medical Oncology Fellowship at the Johns Hopkins Oncology Center.